-

INVESTOR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action Lawsuit Against STAAR Surgical Company

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Central District of California on behalf of those who acquired STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) securities during the period from February 26, 2020 through August 10, 2020 (the “Class Period”). Investors have until October 19, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

According to the Complaint, the Company made false and misleading statements to the market. STAAR is the subject of a report by investment analyst J Capital which alleges that the Company has overstated its sales in China by at least one-third, “meaning all of the Company’s $14 mln in 2019 profit is fake.” The report, based on extensive interviews and research, states that the Company reports fake sales numbers and then marks up marketing costs in a scheme to hide “phantom” revenue. Based on this news, shares of STAAR fell by 6% on August 11, 2020, damaging investors.

If you acquired STAAR securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney at 212-371-6600, by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, and whistleblower litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney’s website: www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq., (212) 371-6600
investigations@kmllp.com
www.kmllp.com

Kirby McInerney LLP

NASDAQ:STAA

Release Versions
$Cashtags

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq., (212) 371-6600
investigations@kmllp.com
www.kmllp.com

Social Media Profiles
More News From Kirby McInerney LLP

INVESTOR ALERT: Securities Class Action Filed Against Soleno Therapeutics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ:SLNO) securities during the period of March 26, 2025 through November 4, 2025, inclusive (“the Class Period”). If you suffered a loss on your Soleno investments, you have until May 5, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submit...

REMINDER: NuScale Power Corporation Investors With Significant Losses Must Act By April 20, 2026

NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP reminds NuScale Power Corporation (“NuScale” or the “Company”) (NYSE:SMR) investors of the April 20, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as...

INVESTOR ALERT: Securities Class Action Filed Against Eos Energy Enterprises, Inc. – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Eos Energy Enterprises, Inc. (“Eos” or the “Company”) (NASDAQ:EOSE) period of November 5, 2025 through February 26, 2026, inclusive (“the Class Period”). If you suffered a loss on your Eos investments, you have until May 5, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted after this deadlin...
Back to Newsroom